Biotech / MedicalBiotech Valuation

Previous 10 Next 10 
To: software salesperson who wrote (37614)12/26/2011 12:29:41 PM
From: BulbaMan
1 Recommendation   of 49904
Also, in case your friend doesn’t already know about the Cutaneous Lymphoma Foundation, they’re an excellent organization. Here’s the link:

Share RecommendKeepReplyMark as Last Read

To: software salesperson who wrote (37614)12/26/2011 3:42:54 PM
From: Biomaven
1 Recommendation   of 49904

This is a very complex disease, and a lot depends on the specifics of the case. So really there is no substitute
for a top heme/onc and a second opinion or two.

This is a good review of the disease constellation:


I'm assuming the isotope tracking is to determine whether the spleen is the site of the platelet destruction, and if so, proceed with a splenectomy. Here's a discussion of this:

Here's a more recent abstract along the same lines:

Am J Hematol. 2011 Nov;86(11):909-13. doi: 10.1002/ajh.22147. Epub 2011 Sep 21.
The scintigraphic index spleen/liver at 30 minutes predicts the success of splenectomy in persistent and chronic primary immune thrombocytopenia.
Roca M, Muñiz-Diaz E, Mora J, Romero-Zayas I, Ramón O, Roig I, Pujol-Moix N.
SourceDepartment of Nuclear Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.

AbstractSplenectomy is considered the second-line of treatment in patients with chronic primary immune thrombocytopenia (ITP) in whom glucocorticoids have failed. Some patients do not respond to splenectomy or they have postoperative complications. Based on our previous experience using kinetic and scintigraphic parameters, we did a retrospective study with the aim of comparing all these parameters as a means of predicting the success of splenectomy in persistent and chronic primary ITP. Forty-one consecutive patients with chronic primary ITP refractory to prednisone, who had been splenectomized, were included in the study. The response to splenectomy was assessed by evaluating bleeding and platelet counts before and at different times after surgery. A complete platelet kinetic study was performed before the splenectomy using autologous (111) In-labeled platelets. The scintigraphic parameters measured included different indices between spleen/heart, liver/hearth, and spleen/liver. Thirty-six patients gave a complete response after splenectomy and five patients did not respond. A statistically significant difference between both groups was found with initial platelet recovery and with some scintigraphic indices which also showed a variable prediction value for the success of splenectomy. Among these indices, the spleen/liver at 30 minutes demonstrated a predictive value with a 100% of sensitivity and a 100% of specificity. Conclusion: some platelet kinetic parameters and scintigraphic indices, in particular the spleen/liver at 30 minutes, were useful to predict the outcome of splenectomy in persistent and chronic primary ITP and, therefore, they should be taken into account when deciding whether or not to perform a splenectomy.

Not sure why this test couldn't be done in the US.

Rigel's SYK inhibitor showed some promising results in ITP, but I don't see any more recent trials.


Share RecommendKeepReplyMark as Last Read

To: DewDiligence_on_SI who wrote (37595)12/27/2011 1:04:33 PM
From: Arthur Radley
1 Recommendation   of 49904

Your favorite company and their CEO--only this guy can make a 'silk purse out of a pig's ear'.
This guy's spin is unbeatable-------makes the FDA people sound like they had already decided to approve his drug as they saw no problems.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Arthur Radley who wrote (37618)12/27/2011 6:52:30 PM
From: DewDiligence_on_SI
   of 49904
>RPRX—Your favorite company and their CEO--only this guy can make a 'silk purse out of a pig's ear'. This guy's spin is unbeatable-------makes the FDA people sound like they had already decided to approve his drug as they saw no problems.<

You’re quite right, Cary—this PR was extreme even for a scam such as RPRX; this is what I posted about it on iHub:

Regards, Dew

Share RecommendKeepReplyMark as Last Read

From: tnsaf12/27/2011 7:50:49 PM
   of 49904



Common Stock

Preferred Stock

Debt Securities



We may issue securities from time to time in one or more offerings. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before you invest.

We may offer these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement.

Our common stock trades on the NASDAQ Global Market under the symbol “AVEO.”

Investing in these securities involves certain risks. See “ Risk Factors” on page 5 of this prospectus and any other risk factors included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2012.


Share RecommendKeepReplyMark as Last Read

From: Pistol Pete12/29/2011 12:26:11 AM
1 Recommendation   of 49904

One Amazing Pharmaceutical Stock To Watch In 2012

A relatively untapped field within the pharmaceutical industry lies in lipid-based therapies, particularly with the use of monoclonal antibodies. One of the top leaders in this emerging field is Lpath Inc. ( LPTN.OB), a small pharmaceutical company which had its IPO at the end of 2005. Leading the company’s research is Roger Sabbadini, a former professor of biology from the Univesity of California, San Diego. His research was heavily focused on the development of antibodies for use against bioactive lipids.

Currently, the vast majority of drugs both on the market and in development target protein pathways. Proteins, unlike lipids, are more complex and highly evolved structures that are specifically evolved for advanced physiological processes. They are mutated more frequently through alterations in genetic data, which is why it can be so difficult to predict the human outcome in clinical trials after animal studies. Lipids, on the other hand, comprise a more fundamental form of physiology. This generally means that the results from earlier clinical trials could be more promising than usual, since lipid pathways are so much more universal.

Additionally, as stated on the company’s website, recent discoveries have implied that lipids have vital functions in physiological pathways that were previously unknown. With the lipidome (essentially the number of types of lipids) offering over 1,000 molecules to study, there is a significant reservoir of untapped clinical application. Due to this, Lpath’s leading position in this new field is of significant interest to both investors and larger pharmaceutical fields looking to expand innovation between product development. Especially important is the firm’s proprietary ImmuneY2 system, which serves as an efficient and optimal way to identify antibodies for use against particular lipids.

What has brought Lpath to the spotlight in the last year is its high-profile partnership with Pfizer ( PFE) that started in 2010 for the development of iSONEP, with the possibility of $500 million in cash given that particular milestones for the drug are met. iSONEP, the most developed drug on the Lpath pipeline, is a treatment for wet AMD (wet age-related macular degeneration - an immense drug market with large growth prospects due to an aging population. Wet AMD occurs upon abnormal growth of blood vessels which damage the macula and leak blood into the eye. Vision is greatly impaired during the advanced stages of the disease, which is why treatments are so greatly sought after.

Currently, treatment for wet AMD is limited to laser surgery to attempt destruction of the abnormal blood vessels, photodynamic therapy which can significantly slow the rate of the disease, and VEGF (vascular endothelial growth factor) inhibiting agents which also slow the progression of AMD. VEGF (angiogenesis / blood vessel growth inhibitor) treatments are popular, and they include Lucentis (developed by Genentech and marketed by Novartis ( NVS)) and Avastin (developed by Genentech and marketed by Roche ( RHHBY.PK)). There are few other options for patients that don’t respond to these drugs.

Lpath began phase 2 clinical trials in October 2011 to test the efficacy of iSONEP, its lipidomics-based therapy, of patients who failed to respond to other blood-vessel inhibiting drugs. The results are due in 2012, and will undoubtedly largely influence the stock’s price. Phase 1 trials have been very positive thus far. In addition to strong tolerance of the drugs in the clinical population, reductions in the size of the actual AMD lesions were observed. Some patients have even seen a complete elimination of the lesions and reduced swelling, which is particularly exciting given that current treatments have not been capable of producing such startlingly positive results.

On top of iSONEP, which has shown exceedingly positive results thus far, the company is also developing the drug ASONEP (entering phase 2 trials in 2012), and two others in very early stages of development. ASONEP is being considered for a very broad range of diseases, and has already found a partner with Pfizer (again) who holds the right of first refusal. Since iSONEP is the most developed product, and has strong data and sizable financial resources supporting its eventual position in the wet AMD market, LPTN will definitely be a stock to watch going into 2012.

This was originally posted on Seeking Alpha. Good read.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Pistol Pete who wrote (37621)12/29/2011 7:49:21 AM
From: DewDiligence_on_SI
   of 49904
LPTN does not impress me at all.

Share RecommendKeepReplyMark as Last ReadRead Replies (3)

From: Arthur Radley12/29/2011 10:22:28 AM
2 Recommendations   of 49904

#5--Right on the money--IMO!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: DewDiligence_on_SI who wrote (37622)12/29/2011 2:00:47 PM
From: ariadough
   of 49904
dew any particular reason you dont like lpnt. i did see were biomed reports was pumping???

i thought it was some interesting pfe was on board?/


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: ariadough who wrote (37624)12/29/2011 5:43:22 PM
From: DewDiligence_on_SI
   of 49904
>Dew, any particular reason you dont like lptn? i did see were BioMedReports was pumping<

LPTN has the outward markings of a scam company in the same mold as, say, PPHM.

The partnership with PFE in AMD is unlikely to bear fruit, IMO. For the Seeking Alpha author to characterize this program as “high profile” is an egregious case of spin insofar as PFE never even mentions it. Regards, Dew

Share RecommendKeepReplyMark as Last ReadRead Replies (2)
Previous 10 Next 10 

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.